Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.

Klotsche J, Minden K, Niewerth M, Horneff G.

Ann Rheum Dis. 2018 Feb 16. pii: annrheumdis-2017-211968. doi: 10.1136/annrheumdis-2017-211968. [Epub ahead of print]

PMID:
29453217
2.

[Myositis-specific antibodies associated with juvenile dermatomyositis].

Eising K, Peitz J, Unterwalder N, Meisel C, Horneff G.

Z Rheumatol. 2018 Feb 6. doi: 10.1007/s00393-017-0415-0. [Epub ahead of print] German.

PMID:
29411095
3.

Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.

Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N, Hufnagel M, Jansson AF, Hedrich C, Winowski H, Berger T, Foeldvari I, Ganser G, Hospach A, Huppertz HI, Mönkemöller K, Neudorf U, Weißbarth-Riedel E, Wittkowski H, Horneff G, Foell D; PRO-KIND SJIA project collaborators.

Pediatr Rheumatol Online J. 2018 Jan 22;16(1):7. doi: 10.1186/s12969-018-0224-2.

4.

S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.

Gohar F, Anink J, Moncrieffe H, Van Suijlekom-Smit LWA, Prince FHM, van Rossum MAJ, Dolman KM, Hoppenreijs EPAH, Ten Cate R, Ursu S, Wedderburn LR, Horneff G, Frosch M, Foell D, Holzinger D.

J Rheumatol. 2018 Jan 15. pii: jrheum.170438. doi: 10.3899/jrheum.170438. [Epub ahead of print]

PMID:
29335345
5.

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.

Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, Horneff G, Smolewska E, Vehe RK, Hazra A, Wang R, Mebus CA, Alvey C, Lamba M, Krishnaswami S, Stock TC, Wang M, Suehiro R, Martini A, Lovell DJ; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG).

Pediatr Rheumatol Online J. 2017 Dec 28;15(1):86. doi: 10.1186/s12969-017-0212-y.

6.

Comorbidity of Type 1 Diabetes Mellitus in Patients with Juvenile Idiopathic Arthritis.

Schenck S, Rosenbauer J, Niewerth M, Klotsche J, Minden K, Schwarz T, Foeldvari I, Horneff G, Weller-Heinemann F, Holl RW, Thon A.

J Pediatr. 2018 Jan;192:196-203. doi: 10.1016/j.jpeds.2017.07.050.

PMID:
29246341
7.

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.

Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP.

Arthritis Res Ther. 2017 Nov 22;19(1):256. doi: 10.1186/s13075-017-1462-2.

8.

Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis.

Horneff G, Klein A, Ganser G, Sailer-Höck M, Günther A, Foeldvari I, Weller-Heinemann F.

Pediatr Rheumatol Online J. 2017 Nov 7;15(1):78. doi: 10.1186/s12969-017-0206-9. Review.

9.

Fluorescence optical imaging in pediatric patients with inflammatory and non-inflammatory joint diseases: a comparative study with ultrasonography.

Beck MC, Glimm AM, Ohrndorf S, Minden K, Trauzeddel R, Werner SG, Horneff G, Backhaus M, Burmester GR, Kallinich T, Girschick H, Klotsche J.

Arthritis Res Ther. 2017 Oct 17;19(1):233. doi: 10.1186/s13075-017-1440-8.

10.

Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative.

Kuemmerle-Deschner JB, Hansmann S, Wulffraat NM, Vastert SJ, Hens K, Anton J, Avcin T, Martini A, Koné-Paut I, Uziel Y, Ravelli A, Wouters C, Shaw D, Özen S, Eikelberg A, Prakken BJ, Ruperto N, Horneff G, Constantin T, Beresford MW, Sikken M, Foster HE, Haug I, Schuller S, Jägle C, Benseler SM.

Ann Rheum Dis. 2018 Mar;77(3):319-327. doi: 10.1136/annrheumdis-2017-211904. Epub 2017 Oct 11.

PMID:
29021237
11.

Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.

Kuemmerle-Deschner JB, Verma D, Endres T, Broderick L, de Jesus AA, Hofer F, Blank N, Krause K, Rietschel C, Horneff G, Aksentijevich I, Lohse P, Goldbach-Mansky R, Hoffman HM, Benseler SM.

Arthritis Rheumatol. 2017 Nov;69(11):2233-2240. doi: 10.1002/art.40208. Epub 2017 Oct 17.

PMID:
28692792
12.

Fluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment - a multicenter non-interventional diagnostic evaluation.

Klein A, Just GW, Werner SG, Oommen PT, Minden K, Becker I, Langer HE, Klee D, Horneff G.

Arthritis Res Ther. 2017 Jun 30;19(1):147. doi: 10.1186/s13075-017-1355-4.

13.

Spontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept.

Klein A, Reinhard H, Mueller AM, Horneff G.

Eur J Rheumatol. 2017 Jun;4(2):136-138. doi: 10.5152/eurjrheum.2016.032. Epub 2017 Feb 23.

14.

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.

Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Velázquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell DJ, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

Ann Rheum Dis. 2018 Jan;77(1):21-29. doi: 10.1136/annrheumdis-2016-210456. Epub 2017 May 15.

15.

A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities.

Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Glerup M, Guzman J, Horneff G, Kearsley-Fleet L, Klein A, Klotsche J, Magnusson B, Minden K, Munro JE, Niewerth M, Nordal E, Ruperto N, Santos MJ, Schanberg LE, Thomson W, van Suijlekom-Smit L, Wulffraat N, Hyrich K.

Pediatr Rheumatol Online J. 2017 Apr 19;15(1):31. doi: 10.1186/s12969-017-0161-5.

16.

Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis.

Horneff G, Peitz J, Kekow J, Foell D.

Scand J Rheumatol. 2017 Nov;46(6):500-501. doi: 10.1080/03009742.2017.1288827. Epub 2017 Mar 7. No abstract available.

PMID:
28266235
17.

[Genetics of autoinflammatory syndromes].

Horneff G, Schmidt RE.

Z Rheumatol. 2017 May;76(4):292-294. doi: 10.1007/s00393-017-0284-6. German. No abstract available.

PMID:
28258405
18.

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.

Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A.

Arthritis Res Ther. 2016 Nov 24;18(1):272.

19.

Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.

Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1113-1120. Epub 2016 Sep 8.

PMID:
27749226
20.

Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.

Windschall D, Horneff G.

Clin Rheumatol. 2016 Dec;35(12):2925-2931. Epub 2016 Oct 5.

PMID:
27709443
21.

Characteristics and outcomes of chronic non-bacterial osteitis in children.

Wintrich S, Horneff G.

Eur J Rheumatol. 2015 Dec;2(4):139-142. Epub 2015 Aug 21.

23.

Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.

Klotsche J, Raab A, Niewerth M, Sengler C, Ganser G, Kallinich T, Niehues T, Hufnagel M, Thon A, Hospach T, Horneff G, Minden K.

Arthritis Rheumatol. 2016 Dec;68(12):3023-3034. doi: 10.1002/art.39796.

24.

Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.

Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, Akikusa JD, Avcin T, Chaitow J, Koskova E, Lauwerys BR, Calvo Penades I, Flato B, Gamir ML, Huppertz HI, Jaller Raad JJ, Jarosova K, Anton J, Macku M, Otero Escalante WJ, Rutkowska-Sak L, Trauzeddel R, Velez-Sanchez PJ, Wouters C, Wajdula J, Zang C, Bukowski J, Woodworth D, Vlahos B, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

J Rheumatol. 2016 Apr;43(4):816-24. doi: 10.3899/jrheum.150430. Epub 2016 Mar 1.

PMID:
26932344
25.

Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.

van Dijkhuizen EH, Pouw JN, Scheuern A, Hügle B, Hardt S, Ganser G, Kümmerle-Deschner JB, Horneff G, Holzinger D, Bulatović Ćalasan M, Wulffraat NM.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):148-54. Epub 2016 Feb 2.

PMID:
26843067
26.

German guidelines for the diagnosis and therapy of localized scleroderma.

Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A, Aberer E, Scharffetter-Kochanek K, Horneff G, Reil E, Weberschock T, Hunzelmann N.

J Dtsch Dermatol Ges. 2016 Feb;14(2):199-216. doi: 10.1111/ddg.12724.

PMID:
26819124
27.

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort.

Sengler C, Klotsche J, Niewerth M, Liedmann I, Föll D, Heiligenhaus A, Ganser G, Horneff G, Haas JP, Minden K.

RMD Open. 2015 Dec 8;1(1):e000074. doi: 10.1136/rmdopen-2015-000074. eCollection 2015.

28.

The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.

Hügle B, Horneff G.

Expert Opin Pharmacother. 2016;17(5):703-14. doi: 10.1517/14656566.2016.1133592. Epub 2016 Jan 13. Review.

PMID:
26678914
29.

Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.

Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weißbarth-Riedel E, Schuetz C, Kallinich T, Krause K, Rietschel C, Horneff G, Benseler SM.

Rheumatology (Oxford). 2016 Apr;55(4):689-96. doi: 10.1093/rheumatology/kev416. Epub 2015 Dec 14.

PMID:
26667214
30.

Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls.

Schmeling H, Mahler M, Levy DM, Moore K, Stevens AM, Wick J, McMillan JD, Horneff G, Assassi S, Charles J, Salazar G, Mayes MD, Silverman ED, Klien-Gitelman M, Lee T, Brunner HI, Reed AM, Fritzler MJ.

J Rheumatol. 2015 Dec;42(12):2419-26. doi: 10.3899/jrheum.150567. Epub 2015 Oct 15.

PMID:
26472409
31.

Biologic-associated infections in pediatric rheumatology.

Horneff G.

Curr Rheumatol Rep. 2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z. Review.

PMID:
26385753
32.

Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.

Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G.

J Rheumatol. 2015 Nov;42(11):2160-5. doi: 10.3899/jrheum.140472. Epub 2015 Sep 15.

PMID:
26373564
33.

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.

Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, Hoppenreijs EP, ten Cate R, Ursu S, Wedderburn LR, Horneff G, Frosch M, Vogl T, Gohar F, Foell D, Roth J, Holzinger D.

Arthritis Res Ther. 2015 Aug 7;17:200. doi: 10.1186/s13075-015-0723-1.

34.

[Autoinflammatory syndromes in childhood].

Horneff G.

Z Rheumatol. 2015 Aug;74(6):511-24; quiz 525. doi: 10.1007/s00393-015-1572-7. Review. German.

PMID:
26238708
35.

A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.

Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, Unnebrink K, Anderson JK.

Arthritis Care Res (Hoboken). 2015 Nov;67(11):1503-12. doi: 10.1002/acr.22657.

36.

Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.

Horneff G.

Expert Opin Drug Saf. 2015 Jul;14(7):1111-26. doi: 10.1517/14740338.2015.1042453. Review.

PMID:
26084637
37.
38.

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).

Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K.

Ann Rheum Dis. 2016 May;75(5):855-61. doi: 10.1136/annrheumdis-annrheumdis-2014-206747. Epub 2015 Apr 29.

PMID:
25926155
39.

Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.

Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.

Arthritis Rheumatol. 2015 May;67(8):2240-9. doi: 10.1002/art.39145.

40.

Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Minoia F, Davì S, Horne A, Bovis F, Demirkaya E, Akikusa J, Ayaz NA, Al-Mayouf SM, Barone P, Bica B, Bolt I, Breda L, De Cunto C, Enciso S, Gallizzi R, Griffin T, Hennon T, Horneff G, Jeng M, Kapovic AM, Lipton JM, Magni Manzoni S, Rumba-Rozenfelde I, Magalhaes CS, Sewairi WM, Stine KC, Vougiouka O, Weaver LK, Davidsone Z, De Inocencio J, Ioseliani M, Lattanzi B, Tezer H, Buoncompagni A, Picco P, Ruperto N, Martini A, Cron RQ, Ravelli A; Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society.

J Rheumatol. 2015 Jun;42(6):994-1001. doi: 10.3899/jrheum.141261. Epub 2015 Apr 15.

PMID:
25877504
41.

Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration.

Moorthy LN, Roy E, Kurra V, Peterson MG, Hassett AL, Lehman TJ, Scott C, El-Ghoneimy D, Saad S, El Feky R, Al-Mayouf S, Dolezalova P, Malcova H, Herlin T, Nielsen S, Wulffraat N, van Royen A, Marks SD, Belot A, Brunner J, Huemer C, Foeldvari I, Horneff G, Saurenman T, Schroeder S, Pratsidou-Gertsi P, Trachana M, Uziel Y, Aggarwal A, Constantin T, Cimaz R, Giani T, Cantarini L, Falcini F, Manzoni SM, Ravelli A, Rigante D, Zulian F, Miyamae T, Yokota S, Sato J, Magalhaes CS, Len CA, Appenzeller S, Knupp SO, Rodrigues MC, Sztajnbok F, de Almeida RG, de Jesus AA, de Arruda Campos LM, Silva C, Lazar C, Susic G, Avcin T, Cuttica R, Burgos-Vargas R, Faugier E, Anton J, Modesto C, Vazquez L, Barillas L, Barinstein L, Sterba G, Maldonado I, Ozen S, Kasapcopur O, Demirkaya E, Benseler S.

Pediatr Rheumatol Online J. 2014 Nov 25;12:49. doi: 10.1186/1546-0096-12-49. eCollection 2014.

42.

Treatment of systemic-onset juvenile arthritis with canakinumab.

Peitz J, Horneff G.

Open Access Rheumatol. 2015 Feb 18;7:23-31. eCollection 2015. Review.

43.

Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.

Nimmrich S, Horneff G.

Rheumatol Int. 2015 Mar;35(3):465-70. doi: 10.1007/s00296-014-3197-6. Epub 2015 Jan 13.

PMID:
25583050
44.

[Current news from the BIKER register].

Horneff G, Minden K, Foeldvari I, Onken N, Windschall D, Hospach A, Ganser G, Klotsche J, Becker I; BIKER-Register Studiengruppe.

Z Rheumatol. 2014 Dec;73(10):897-906. doi: 10.1007/s00393-014-1397-9. German.

PMID:
25269873
45.

Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.

Windschall D, Müller T, Becker I, Horneff G.

Rheumatol Int. 2015 Apr;35(4):613-8. doi: 10.1007/s00296-014-3125-9. Epub 2014 Sep 11.

PMID:
25208527
46.

Predictors of response to methotrexate in juvenile idiopathic arthritis.

Albarouni M, Becker I, Horneff G.

Pediatr Rheumatol Online J. 2014 Aug 13;12:35. doi: 10.1186/1546-0096-12-35. eCollection 2014.

47.

Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

Schmeling H, Horneff G, Benseler SM, Fritzler MJ.

Nat Rev Rheumatol. 2014 Nov;10(11):682-90. doi: 10.1038/nrrheum.2014.140. Epub 2014 Aug 12. Review.

PMID:
25112604
48.

[Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].

Niewerth M, Minden K, Klotsche J, Horneff G.

Z Rheumatol. 2014 Aug;73(6):532-40. doi: 10.1007/s00393-014-1378-z. German.

PMID:
25096586
49.

[Development of consensus treatment plans for juvenile localized scleroderma].

Horneff G.

Z Rheumatol. 2014 Jun;73(5):399. German. No abstract available.

PMID:
25057523
50.

[Effectiveness of interleukin-1 inhibiton for mevalonate kinase deficiency].

Horneff G.

Z Rheumatol. 2014 Jun;73(5):398. German. No abstract available.

PMID:
25057522

Supplemental Content

Loading ...
Support Center